Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs Archer Aviation Inc (ACHR) Price & Performance

AbbVie IncTrade
Archer Aviation IncTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Archer Aviation Inc — how do they compare? AbbVie Inc trades at $250.09 (market cap $438.19B), while Archer Aviation Inc trades at $6.8 (market cap $4.78B). The key difference: AbbVie Inc is far larger — about 91.7× Archer Aviation Inc's market cap, and AbbVie Inc pays a 2.79% dividend while Archer Aviation Inc pays none. Which is the better fit depends on your goals.

ABBVACHR
Market Cap
$438.19B$4.78B
Sector
HealthIndustrials
52-Week High
$263.58$13.64
52-Week Low
$197.38$4.44
Enterprise Value
$502.45B$3.12B
Dividend Yield
2.79%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.

Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.

Archer Aviation Inc

Archer Aviation (ACHR) trades at $5.59, up 6.88% today, with a bullish technical signal from moving averages. The company reported a Q2 2026 loss of $0.34 per share, missing estimates, but revenue trends show growth from $300,000 in 2025 to $2 million in 2026. Recent news highlights a transformative deal with Boeing to acquire Wisk Aero, Insitu, and SkyGrid, expanding into autonomous aviation and defense, which spurred a stock surge and high options trading activity.

The outlook is optimistic due to strategic expansion and strong analyst support, with 78% buy ratings and a 78.7% upside price target. However, risks include persistent losses, negative cash flow from operations, and execution challenges in scaling new businesses, requiring careful monitoring of profitability milestones.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About Archer Aviation Inc

Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.

Read more on ACHR